Home Biosimilar Antibodies Others Others Tinurilimab (Anti-CEACAM6 / CD66c)
For research use only. Not for use in humans.

Tinurilimab (Anti-CEACAM6 / CD66c)

Synonyms: CD66c,CEACAM6

Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD.

Tinurilimab (Anti-CEACAM6 / CD66c)

Quality Control

Batch: A254301 Purity: 99% Protein concentration: 5.8mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD.

Product Details

CAS No. 2226224-30-0
Molecular Weight 145.5 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03596372 COMPLETED Drug: BAY1834942 Advanced CEACAM6-expressing Solid Tumors Bayer 2018-06-19 PHASE1

(data from https://clinicaltrials.gov, updated on 2022-06-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.